scPharmaceuticals Inc.

NasdaqGS:SCPH Stock Report

Market Cap: US$169.6m

scPharmaceuticals Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

John Tucker

Chief executive officer

US$1.8m

Total compensation

CEO salary percentage32.8%
CEO tenure7.9yrs
CEO ownership0.2%
Management average tenureno data
Board average tenure7.1yrs

Recent management updates

Recent updates

scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Nov 19
scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Slammed 26% But Getting In Cheap Might Be Difficult Regardless

Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term

Nov 18
Downgrade: Here's How Analysts See scPharmaceuticals Inc. (NASDAQ:SCPH) Performing In The Near Term

Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

Jun 27
Is scPharmaceuticals (NASDAQ:SCPH) Using Too Much Debt?

scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

Jun 27
scPharmaceuticals Inc. (NASDAQ:SCPH) Stocks Shoot Up 26% But Its P/S Still Looks Reasonable

The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Mar 16
The scPharmaceuticals Inc. (NASDAQ:SCPH) Full-Year Results Are Out And Analysts Have Published New Forecasts

Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

Nov 25
Is scPharmaceuticals (NASDAQ:SCPH) Using Debt Sensibly?

scPharmaceuticals: Furoscix Approval A Potential Paradigm Shift For Heart Failure Patients

Oct 20

FDA approves scPharmaceuticals Furoscix to treat congestion in heart failure

Oct 10

Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Jan 11
Does scPharmaceuticals (NASDAQ:SCPH) Have A Healthy Balance Sheet?

Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

Sep 02
Is scPharmaceuticals (NASDAQ:SCPH) A Risky Investment?

scPharmaceuticals: We Still See A High Probability Of Success For FUROSCIX

Aug 26

Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

Mar 09
Here's What scPharmaceuticals Inc.'s (NASDAQ:SCPH) Shareholder Ownership Structure Looks Like

How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

Nov 24
How Many scPharmaceuticals Inc. (NASDAQ:SCPH) Shares Do Institutions Own?

CEO Compensation Analysis

How has John Tucker's remuneration changed compared to scPharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$80m

Jun 30 2024n/an/a

-US$61m

Mar 31 2024n/an/a

-US$58m

Dec 31 2023US$2mUS$604k

-US$55m

Sep 30 2023n/an/a

-US$50m

Jun 30 2023n/an/a

-US$45m

Mar 31 2023n/an/a

-US$40m

Dec 31 2022US$2mUS$580k

-US$37m

Sep 30 2022n/an/a

-US$35m

Jun 30 2022n/an/a

-US$31m

Mar 31 2022n/an/a

-US$29m

Dec 31 2021US$2mUS$550k

-US$28m

Sep 30 2021n/an/a

-US$28m

Jun 30 2021n/an/a

-US$31m

Mar 31 2021n/an/a

-US$32m

Dec 31 2020US$2mUS$531k

-US$32m

Sep 30 2020n/an/a

-US$35m

Jun 30 2020n/an/a

-US$32m

Mar 31 2020n/an/a

-US$31m

Dec 31 2019US$1mUS$514k

-US$33m

Sep 30 2019n/an/a

-US$27m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$29m

Dec 31 2018US$1mUS$494k

-US$29m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$28m

Dec 31 2017US$2mUS$380k

-US$24m

Compensation vs Market: John's total compensation ($USD1.84M) is about average for companies of similar size in the US market ($USD1.44M).

Compensation vs Earnings: John's compensation has increased whilst the company is unprofitable.

CEO

John Tucker (61 yo)

7.9yrs

Tenure

US$1,838,662

Compensation

Mr. John H. Tucker has been the Chief Executive Officer and President of scPharmaceuticals Inc. (alternate name: scPharmaceuticals LLC) since January 30, 2017 and serves as its Principal Executive Officer...

Board Members

NamePositionTenureCompensationOwnership
John Tucker
President8.9yrsUS$1.84m0.18%
$ 307.3k
Leonard Schaeffer
Independent Director10yrsUS$184.55k0.11%
$ 184.6k
Jack Khattar
Independent Chairman of the Board8.5yrsUS$227.05k0.010%
$ 16.9k
Mette Agger
Independent Director10.8yrsUS$189.55k0%
$ 0
Klaus Veitinger
Independent Director7.1yrsUS$187.05k0%
$ 0
Marvin Konstam
Member of Scientific Advisory Boardno datano datano data
William Abraham
Independent Director3.8yrsUS$182.05k0%
$ 0
Minnie Baylor-Henry
Independent Director6.4yrsUS$187.05k0%
$ 0
Frederick Hudson
Independent Director6.5yrsUS$197.05k0%
$ 0
Sara Bonstein
Independent Director4.4yrsUS$187.05k0%
$ 0
G. Felker
Member of Scientific Advisory Boardno datano datano data
Dan Bensimhon
Member of Scientific Advisory Boardno datano datano data

7.1yrs

Average Tenure

63yo

Average Age

Experienced Board: SCPH's board of directors are considered experienced (7.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 13:37
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

scPharmaceuticals Inc. is covered by 11 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Gary NachmanBMO Capital Markets Equity Research
null nullBMO Capital Markets Equity Research
Chase KnickerbockerCraig-Hallum Capital Group LLC